DE69418699T2 - Induktion der antworten zytotoxischer t-lymphozyten - Google Patents

Induktion der antworten zytotoxischer t-lymphozyten

Info

Publication number
DE69418699T2
DE69418699T2 DE69418699T DE69418699T DE69418699T2 DE 69418699 T2 DE69418699 T2 DE 69418699T2 DE 69418699 T DE69418699 T DE 69418699T DE 69418699 T DE69418699 T DE 69418699T DE 69418699 T2 DE69418699 T2 DE 69418699T2
Authority
DE
Germany
Prior art keywords
replicating
mammalian host
protein antigen
methods
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69418699T
Other languages
English (en)
Other versions
DE69418699D1 (de
Inventor
Kenneth Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of DE69418699D1 publication Critical patent/DE69418699D1/de
Application granted granted Critical
Publication of DE69418699T2 publication Critical patent/DE69418699T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical
DE69418699T 1993-01-11 1994-01-10 Induktion der antworten zytotoxischer t-lymphozyten Expired - Lifetime DE69418699T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US323393A 1993-01-11 1993-01-11
PCT/US1994/000362 WO1994015635A1 (en) 1993-01-11 1994-01-10 Inducing cytotoxic t lymphocyte responses

Publications (2)

Publication Number Publication Date
DE69418699D1 DE69418699D1 (de) 1999-07-01
DE69418699T2 true DE69418699T2 (de) 1999-09-30

Family

ID=21704843

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69418699T Expired - Lifetime DE69418699T2 (de) 1993-01-11 1994-01-10 Induktion der antworten zytotoxischer t-lymphozyten

Country Status (11)

Country Link
US (2) US5928647A (de)
EP (1) EP0678034B1 (de)
JP (1) JPH08505625A (de)
AT (1) ATE180407T1 (de)
AU (1) AU679041B2 (de)
CA (1) CA2153391C (de)
DE (1) DE69418699T2 (de)
DK (1) DK0678034T3 (de)
ES (1) ES2131676T3 (de)
GR (1) GR3030568T3 (de)
WO (1) WO1994015635A1 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0686030T3 (da) * 1993-12-23 2001-06-25 Rmf Dictagene Sa Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler
CA2200550A1 (en) * 1994-09-23 1996-04-04 Kuang Hsu Chitosan induced immunopotentiation
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
ATE238668T1 (de) * 1995-01-17 2003-05-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelialer transport von immunogenen
DE19511276C2 (de) * 1995-03-27 1999-02-18 Immuno Ag Adjuvans auf der Basis kolloidaler Eisenverbindungen
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP0991403B1 (de) * 1997-01-30 2003-04-02 Chiron Corporation Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
EP1275380A1 (de) * 1997-01-30 2003-01-15 Chiron Corporation Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6254890B1 (en) * 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP1221968B1 (de) * 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Verfahren zur erhaltung zellimmuneantworten gegen proteinen
PT1265915E (pt) 2000-02-23 2011-02-07 Glaxosmithkline Biolog Sa Novos compostos
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20010036463A1 (en) * 2000-03-09 2001-11-01 Compans Richard W. Transcutaneous immunization for large particulate antigens
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
ATE396265T1 (de) 2000-06-28 2008-06-15 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
JP2004509914A (ja) 2000-09-28 2004-04-02 カイロン　コーポレイション 微粒子組成物およびその製造方法
WO2002026209A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticles for delivery of the heterologous nucleic acids
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
NZ530315A (en) 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2003223285A1 (en) * 2002-03-13 2003-09-29 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20040170606A1 (en) * 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
CA2486118A1 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
CA2489410C (en) * 2002-07-17 2015-01-13 Cytos Biotechnology Ag Molecular antigen arrays
KR20120041739A (ko) * 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
WO2004100984A1 (en) * 2003-05-13 2004-11-25 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
EP1636270B1 (de) 2003-06-16 2016-07-20 UCB Pharma S.A. Spezifische antikörper für sclerostin und verfahren zur erhöhung der knochenmineralisierung
EP1682159A4 (de) * 2003-10-16 2010-07-21 Stephen John Ralph Immunomodulierende zusammensetzungen und ihre verwendungen
CN1905903A (zh) * 2004-01-20 2007-01-31 赛托斯生物技术公司 生长素释放肽－载体偶联物
EP1766096B1 (de) 2004-05-25 2013-01-02 Oregon Health and Science University Hiv-impfung mit impfvektoren auf hcmv-basis
CN101119749A (zh) * 2004-10-25 2008-02-06 赛托斯生物技术公司 肠抑胃肽(gip)抗原阵列及其用途
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
EP2392347A3 (de) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Impfstoffe gegen Chlamydieninfektion
CN101273055B (zh) 2005-04-29 2016-03-16 葛兰素史密丝克莱恩生物有限公司 用于预防或治疗结核分枝杆菌感染的新方法
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
EP2010226B1 (de) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
EP2134830A2 (de) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oszillations-zellkultur-bioreaktor
JP5391387B2 (ja) * 2007-03-09 2014-01-15 小川 一文 磁気感応性薬剤およびその製造方法
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
ES2627292T3 (es) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
WO2010042759A2 (en) 2008-10-08 2010-04-15 Kyphia Pharmaceuticals Inc Gaba conjugates and methods of use thereof
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
AU2010254551B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
BR112012003977A2 (pt) * 2009-08-26 2017-06-06 Selecta Biosciences Inc composições que induzem ajuda de célula t
DK2477652T3 (en) 2009-09-16 2015-07-20 Vaxart Inc Immunization strategy for the prevention of infection H1Ni
EP2905332B1 (de) 2009-11-19 2018-09-12 Solis BioDyne OÜ Zusammensetzungen zur erhöhung der polypeptidstabilität und -aktivität und zugehörige verfahren
WO2011092253A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
DK2601609T3 (en) 2010-08-02 2017-06-06 Population Bio Inc COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
BR122015005121B1 (pt) 2011-03-08 2022-01-25 Sagimet Biosciences Inc Compostos moduladores heterocíclicos de síntese de lipídios, composição farmacêutica que compreende os mesmos, bem como usos dos ditos compostos para tratar uma infecção viral, uma condição que tem como uma característica a desregulação de uma função de ácido graxo sintase e câncer
CN103517707A (zh) 2011-04-29 2014-01-15 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
EP2766483B1 (de) 2011-10-10 2022-03-23 The Hospital For Sick Children Verfahren und zusammensetzungen zum screening und zur behandlung von entwicklungsstörungen
EP2773779B1 (de) 2011-11-04 2020-10-14 Population Bio, Inc. Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2863887C (en) 2012-02-09 2023-01-03 Population Diagnostics, Inc. Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
WO2014043519A1 (en) 2012-09-14 2014-03-20 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US10226449B2 (en) 2013-12-20 2019-03-12 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
CA2935767C (en) 2014-01-07 2023-01-31 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
US20170224805A1 (en) 2014-02-20 2017-08-10 Vaxart, Inc. Formulations for small intestinal delivery
CN113403338A (zh) 2014-03-28 2021-09-17 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
WO2016036403A1 (en) 2014-09-05 2016-03-10 Population Diagnostics Inc. Methods and compositions for inhibiting and treating neurological conditions
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
EP3212001A4 (de) 2014-10-31 2018-04-25 Whole Biome Inc. Verfahren und zusammensetzungen im zusammenhang mit mikrobieller behandlung und diagnose von störungen
EP3277675B1 (de) 2015-03-19 2022-01-19 Sagimet Biosciences Inc. Heterocyclische lipidsynthesemodulatoren
AU2016274599B2 (en) 2015-06-12 2021-09-02 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
AU2017259821A1 (en) 2016-05-04 2018-12-13 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
KR102627561B1 (ko) 2018-06-29 2024-01-24 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
WO2020033700A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
CN112584874A (zh) 2018-08-20 2021-03-30 武汉纽福斯生物科技有限公司 用于治疗莱伯氏遗传性视神经病变的组合物和方法
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
CN113025633A (zh) 2019-12-09 2021-06-25 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023280157A1 (zh) 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
CN116024266A (zh) 2021-08-06 2023-04-28 武汉纽福斯生物科技有限公司 用于治疗由于nd4突变造成的莱伯氏遗传性视神经病变的组合物和方法
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4804624A (en) * 1982-05-21 1989-02-14 The University Of Tennessee Research Corporation Passive agglutination assay for pseudorabies antibody
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
GB2160312B (en) 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US5078998A (en) 1985-08-02 1992-01-07 Bevan Michael J Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen
US5194254A (en) 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
GB8610983D0 (en) 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US5041385A (en) 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5008116A (en) 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
WO1990007322A1 (en) 1988-12-19 1990-07-12 David Gordon Diagnosis and treatment of viral effects
US5021551A (en) 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US5045320A (en) * 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
DK0531401T3 (da) * 1990-05-10 1997-07-28 Dana Farber Cancer Inst Inc Forøgelse af associationen af exogene peptider med MHC klasse I molekyler til immunsystemets celler.
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
CA2110682A1 (en) 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
FR2682114B1 (fr) * 1991-10-03 1996-02-23 Pasteur Merieux Serums Vacc Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
CA2123696C (en) 1991-11-26 2002-07-02 Lynn E. Spitler Antitumor vaccines

Also Published As

Publication number Publication date
AU6086594A (en) 1994-08-15
EP0678034A1 (de) 1995-10-25
US6328972B1 (en) 2001-12-11
DK0678034T3 (da) 1999-11-08
CA2153391C (en) 2000-08-15
ES2131676T3 (es) 1999-08-01
DE69418699D1 (de) 1999-07-01
AU679041B2 (en) 1997-06-19
CA2153391A1 (en) 1994-07-21
ATE180407T1 (de) 1999-06-15
WO1994015635A1 (en) 1994-07-21
GR3030568T3 (en) 1999-10-29
JPH08505625A (ja) 1996-06-18
EP0678034B1 (de) 1999-05-26
US5928647A (en) 1999-07-27

Similar Documents

Publication Publication Date Title
DE69418699D1 (de) Induktion der antworten zytotoxischer t-lymphozyten
Feng et al. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity
CA2123580A1 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
Barr et al. A potent adjuvant effect of CD40 antibody attached to antigen
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GR3015791T3 (en) Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
ATE286744T1 (de) Stress protein peptid komplexe als prophylaktische und therapeutische impfstoffe gegen intrazelluläre pathogene
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
GB2255093A (en) Hiv-1 core protein fragments
EP0634937A1 (de) Impfstoffe die nicht ionische tensid vesikeln enthalften.
CA2001328A1 (en) Borrelia antigen
NZ326092A (en) Immunostimulatory composition and method
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
CA2078235A1 (en) Idiotypic vaccination against b cell lymphoma
CA2055615A1 (en) Monoclonal antibodies for inducing tolerance
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
EP0531401A4 (en) Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
Lees et al. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
WO2001059073A3 (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition